Pirtobrutinib monotherapy in Bruton tyrosine kinase inhibitor-intolerant patients with B-cell malignancies: results of the phase I/II BRUIN trial
Nirav N. Shah(Medical College of Wisconsin), Jennifer R. Brown(Dana-Farber Cancer Institute), Marc Hoffmann(The University of Kansas Cancer Center), Jonathon B. Cohen(Emory University), Richard A. Walgren(Eli Lilly (United States)), Nicole Lamanna(Memorial Sloan Kettering Cancer Center), Jennifer A. Woyach(The University of Texas MD Anderson Cancer Center), Minal Barve(Mary Crowley Cancer Research Center), Catherine C. Coombs(Memorial Sloan Kettering Cancer Center), Talha Munir(Leeds Teaching Hospitals NHS Trust), Ewa Lech‐Marańda(Instytut Hematologii i Transfuzjologi), Donald E. Tsai(University of Pennsylvania), Krish Patel, James N. Gerson(UPMC Hillman Cancer Center), Lindsey E. Roeker(Memorial Sloan Kettering Cancer Center), Katherine Bao(Loxo Oncology at Lilly (United States)), Hong‐Mei Han(Loxo Oncology at Lilly (United States)), Nicholas A. Cangemi(Loxo Oncology at Lilly (United States)), Toby A. Eyre(Oxford University Hospitals NHS Trust), Meghan C. Thompson(Memorial Sloan Kettering Cancer Center), Chan Y. Cheah(The University of Western Australia), Jennifer Kherani(Peter MacCallum Cancer Centre), Michael Wang(The University of Texas MD Anderson Cancer Center), Chaitra S. Ujjani(Fred Hutch Cancer Center), Shuo Ma(Nantong University), Bita Fakhri(University of California, San Francisco), Alvaro J. Alencar(University of Miami), Paolo Ghia(Vita-Salute San Raffaele University), William G. Wierda(University of Maryland, Baltimore), Wojciech Jurczak(The Maria Sklodowska-Curie National Research Institute of Oncology), Pier Luigi Zinzani(Istituto Oncologico Romagnolo), Amy S. Ruppert(The University of Texas MD Anderson Cancer Center), Ian W. Flinn(Tennessee Oncology), Won Seog Kim(Samsung Medical Center), Manish R. Patel(Sarah Cannon)
Cited by 12
Related Papers
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k